186 related articles for article (PubMed ID: 12125509)
1. Taxol reactions.
Price KS; Castells MC
Allergy Asthma Proc; 2002; 23(3):205-8. PubMed ID: 12125509
[TBL] [Abstract][Full Text] [Related]
2. Mast cells activation and high blood tryptase levels due to paclitaxel administration. Is Cremophor EL the culprit?: A case report.
D'Errico S; Baldari B; Arcangeli M; Santurro A; Frati P; Fineschi V
Medicine (Baltimore); 2020 Oct; 99(43):e22814. PubMed ID: 33120804
[TBL] [Abstract][Full Text] [Related]
3. Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions.
Micha JP; Goldstein BH; Birk CL; Rettenmaier MA; Brown JV
Gynecol Oncol; 2006 Feb; 100(2):437-8. PubMed ID: 16226797
[TBL] [Abstract][Full Text] [Related]
4. Hypersensitivity reactions in ovarian cancer patients receiving paclitaxel.
Cormio G; Di Vagno G; Melilli GA; Cazzolla A; Di Gesù G; Carriero C; Cramarossa D; Loverro G; Selvaggi L
J Chemother; 1999 Oct; 11(5):407-9. PubMed ID: 10632389
[TBL] [Abstract][Full Text] [Related]
5. Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity.
Moon C; Verschraegen CF; Bevers M; Freedman R; Kudelka AP; Kavanagh JJ
Anticancer Drugs; 2000 Aug; 11(7):565-8. PubMed ID: 11036959
[TBL] [Abstract][Full Text] [Related]
6. Hypersensitivity reactions in paclitaxel treatment of ovarian cancer patients.
Lehoczky O; Bagaméri A; Udvary J; Pulay T
J Obstet Gynaecol; 2002 May; 22(3):312-3. PubMed ID: 12521509
[No Abstract] [Full Text] [Related]
7. Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy.
Sendo T; Sakai N; Itoh Y; Ikesue H; Kobayashi H; Hirakawa T; Nakano H; Oishi R
Cancer Chemother Pharmacol; 2005 Jul; 56(1):91-6. PubMed ID: 15791461
[TBL] [Abstract][Full Text] [Related]
8. Single-dose dexamethasone paclitaxel premedication.
Micha JP; Rettenmaier MA; Dillman R; Fraser P; Birk C; Brown JV
Gynecol Oncol; 1998 May; 69(2):122-4. PubMed ID: 9600818
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel as an alternative to paclitaxel after acute hypersensitivity reactions.
Bernstein BJ
Ann Pharmacother; 2000 Nov; 34(11):1332-5. PubMed ID: 11098349
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel: a new antineoplastic agent for refractory ovarian cancer.
Gregory RE; DeLisa AF
Clin Pharm; 1993 Jun; 12(6):401-15. PubMed ID: 7691462
[TBL] [Abstract][Full Text] [Related]
11. Emergency. Chemotherapy-induced hypersensitivity reaction.
Myers JS; Kearney K
Am J Nurs; 2000 Apr; 100(4):53-4. PubMed ID: 10776352
[No Abstract] [Full Text] [Related]
12. Hypersensitivity reactions from taxol.
Weiss RB; Donehower RC; Wiernik PH; Ohnuma T; Gralla RJ; Trump DL; Baker JR; Van Echo DA; Von Hoff DD; Leyland-Jones B
J Clin Oncol; 1990 Jul; 8(7):1263-8. PubMed ID: 1972736
[TBL] [Abstract][Full Text] [Related]
13. Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity.
Foa R; Norton L; Seidman AD
Int J Clin Lab Res; 1994; 24(1):6-14. PubMed ID: 7910054
[TBL] [Abstract][Full Text] [Related]
14. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-13-S19-15. PubMed ID: 9427258
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic effect of pemirolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancer.
Yahata H; Saito M; Sendo T; Itoh Y; Uchida M; Hirakawa T; Nakano H; Oishi R
Int J Cancer; 2006 May; 118(10):2636-8. PubMed ID: 16353140
[TBL] [Abstract][Full Text] [Related]
16. Taxol hypersensitivity: rapid retreatment is safe and cost effective.
Olson JK; Sood AK; Sorosky JI; Anderson B; Buller RE
Gynecol Oncol; 1998 Jan; 68(1):25-8. PubMed ID: 9454655
[TBL] [Abstract][Full Text] [Related]
17. [Taxol (paclitaxel) as second-line therapy in breast and ovarian cancer].
Borovik R; Steiner M; Atad J; Sneiderman B; Rosenberg T; Palti S
Harefuah; 1998 Apr; 134(8):605-8, 671. PubMed ID: 10911422
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacological action of paclitaxel].
Potemski P; Płuzańska A
Pol Merkur Lekarski; 1999 Jan; 6(31):27-9. PubMed ID: 10344150
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview.
Hájek R; Vorlicek J; Slavik M
Neoplasma; 1996; 43(3):141-54. PubMed ID: 8841500
[TBL] [Abstract][Full Text] [Related]
20. Eosinophilic ascites: taxol-induced hypersensitivity?
Kobayashi TK; Muramatsu M; Ueda M; Nishino T; Bamba M; Urabe M; Moritani S
Cytopathology; 2004 Jun; 15(3):171-2. PubMed ID: 15165278
[No Abstract] [Full Text] [Related]
[Next] [New Search]